The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Quantitative high-throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical libraries
Open accessAbstract
High-throughput screening (HTS) of chemical compounds to identify modulators of molecular targets is a mainstay of pharmaceutical development. Increasingly, HTS is being used to identify chemical probes of gene, pathway, and cell functions, with the ultimate goal of comprehensively delineating relationships between chemical structures and biological activities. Achieving this goal will require methodologies that efficiently generate pharmacological data from the primary screen and reliably profile the range of biological activities associated with large chemical libraries. Traditional HTS, which tests compounds at a single concentration, is not suited to this task, because HTS is burdened by frequent false positives and false negatives and requires extensive follow-up testing. We have developed a paradigm, quantitative HTS (qHTS), tested with the enzyme pyruvate kinase, to generate concentration–response curves for >60,000 compounds in a single experiment. We show that this method is precise, refractory to variations in sample preparation, and identifies compounds with a wide range of activities. Concentration–response curves were classified to rapidly identify pyruvate kinase activators and inhibitors with a variety of potencies and efficacies and elucidate structure–activity relationships directly from the primary screen. Comparison of qHTS with traditional single-concentration HTS revealed a high prevalence of false negatives in the single-point screen. This study demonstrates the feasibility of qHTS for accurately profiling every compound in large chemical libraries (>10 5 compounds). qHTS produces rich data sets that can be immediately mined for reliable biological activities, thereby providing a platform for chemical genomics and accelerating the identification of leads for drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Enzyme kinetics; behavior and analysis of rapid equilibrium and steady state enzyme systems
(1994) · International Journal of Biochemistry · doi:10.1016/0020-711x(94)90021-3 · Cited by 2,972
The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves
Hill, A. V., Hill, A. L., & Hill, A. V. (1910) · The Journal of Physiology · Cited by 2,181
Crystal structure of the Src family tyrosine kinase Hck
Sicheri, F., Moarefi, I., & Kuriyan, J. (1997) · Nature · doi:10.1038/385602a0 · Cited by 1,172
Statistical practice in high-throughput screening data analysis
Malo, N., Hanley, J. A., Cerquozzi, S., Pelletier, J., & Nadon, R. (2006) · Nature Biotechnology · doi:10.1038/nbt1186 · Cited by 721
Berg, K. A., Maayani, S., Goldfarb, J., Scaramellini, C., Leff, P., & Clarke, W. P. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.1.94 · Cited by 510
NIH Molecular Libraries Initiative
Austin, C. P., Brady, L. S., Insel, T. R., & Collins, F. S. (2004) · Science · doi:10.1126/science.1105511 · Cited by 348
Self-citationHigh-throughput assays for promiscuous inhibitors
Feng, B. Y., Shelat, A., Doman, T. N., Guy, R. K., & Shoichet, B. K. (2005) · Nature Chemical Biology · doi:10.1038/nchembio718 · Cited by 336
Novel Receptor Partners and Function of Receptor Activity-modifying Proteins
Christopoulos, A., Christopoulos, G., Morfis, M., Udawela, M., Laburthe, M., Couvineau, A., Kuwasako, K., Tilakaratne, N., & Sexton, P. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200629200 · Cited by 309
Pyruvate kinase: current status of regulatory and functional properties
Enriqueta Muñoz, M., & Ponce, E. (2003) · Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology · doi:10.1016/s1096-4959(03)00081-2 · Cited by 208
Eastwood, B. J., Farmen, M. W., Iversen, P. W., Craft, T. J., Smallwood, J. K., Garbison, K. E., DeLapp, N. W., & Smith, G. F. (2006) · SLAS DISCOVERY · doi:10.1177/1087057105285611 · Cited by 125
Predicting therapeutic value in the lead optimization phase of drug discovery
Kenakin, T. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1110 · Cited by 106
Glick, M., Jenkins, J. L., Nettles, J. H., Hitchings, H., & Davies, J. W. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci050374h · Cited by 105
Purification and Properties of Acetate Kinase from Bacillus stearothermophilus
Nakajima, H., Suzuki, K., & Imahori, K. (1978) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a132108 · Cited by 102
Computational chemistry-driven decision making in lead generation
Schnecke, V., & Boström, J. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03703-7 · Cited by 77
Popa-Burke, I. G., Issakova, O., Arroway, J. D., Bernasconi, P., Chen, M., Coudurier, L., Galasinski, S., Jadhav, A., Janzen, W., Lagasca, D., et al. (2004) · Analytical Chemistry · doi:10.1021/ac0491859 · Cited by 73
Self-citationEvaluating Real-Life High-Throughput Screening Data
Gribbon, P. M., Lyons, R., Laflin, P., Bradley, J., Chambers, C., Williams, B. S., Keighley, W. W., & Sewing, A. (2005) · SLAS DISCOVERY · doi:10.1177/1087057104271957 · Cited by 71
Buxser, S. E., & Vroegop, S. M. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2005.01.034 · Cited by 26
Assessing the Minimum Number of Data Points Required for Accurate IC 50 Determination
Turner, R. J., & Charlton, S. J. (2005) · Assay and Drug Development Technologies · doi:10.1089/adt.2005.3.525 · Cited by 24
Cited by
Molecular Docking and Structure-Based Drug Design Strategies
Ferreira, L., Dos Santos, R., Oliva, G., & Andricopulo, A. (2015) · Molecules · doi:10.3390/molecules200713384 · Cited by 2,528
Toxicity Testing in the 21st Century: A Vision and a Strategy
Krewski, D., Acosta, D., Andersen, M., Anderson, H., Bailar, J. C., Boekelheide, K., Brent, R., Charnley, G., Cheung, V. G., Green, S., et al. (2010) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2010.483176 · Cited by 1,688
Xu, M., Lee, E. M., Wen, Z., Cheng, Y., Huang, W.-K., Qian, X., TCW, J., Kouznetsova, J., Ogden, S. C., Hammack, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4184 · Cited by 641
Self-citationTransforming Environmental Health Protection
Collins, F. S., Gray, G. M., & Bucher, J. R. (2008) · Science · doi:10.1126/science.1154619 · Cited by 630
The influence of lead discovery strategies on the properties of drug candidates
Keserü, G. M., & Makara, G. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2796 · Cited by 628
Metadata
- Authors
- Inglese, J., Auld, D. S., Jadhav, A., Johnson, R. L., Simeonov, A., Yasgar, A., Zheng, W., & Austin, C. P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2006-08
- Volume
- 103
- Issue
- 31
- Pages
- 11473-11478
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2128879247
- Cited by
- 792
- References
- 22
- FWCI
- 41.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.